MedTrace Logo

A Clinical Trial to Evaluate the Effects of a Supplement on Symptoms Associated With Hormone Imbalance

NCT07765381 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-08-14

No results posted yet for this study

Summary

This study evaluates the effects of the Love Wellness Hello Burn, Balance supplement on symptoms associated with hormone imbalance, as measured by energy levels and healthy eating choices and habits. The trial is a single-arm, open-label, virtual study conducted over 4 weeks, in which all 40 enrolled participants will take the test product daily.

Participants will complete self-reported questionnaires at Baseline, after First Use (within 1-3 hours of use), and at Weeks 1, 2, 3, and 4 to assess changes in symptoms associated with hormonal imbalance, energy levels, healthy eating choices and habits, metabolism, and overall product efficacy.

Conditions

  • Hormone Imbalance
  • Thyroid Hormone Imbalance
  • Low Energy
  • Metabolic Symptoms
  • Unhealthy Eating Habits

Interventions

DIETARY_SUPPLEMENT

Hello Burn, Balance Supplement

All participants take 2 capsules of the Love Wellness Hello Burn, Balance supplement once daily in the morning with a glass of water during the first meal of the day for 4 weeks. The supplement contains selenium (as L-selenomethionine) 55 mcg, chromium (as chromium polynicotinate) 35 mcg, Hello Burn Blend (L-carnitine tartrate, organic green tea leaf powder) 1250 mcg, hypromellose capsule, microcrystalline cellulose, and magnesium stearate.

Sponsors & Collaborators

  • Citruslabs

    collaborator INDUSTRY

  • Love Wellness

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-24
Primary Completion
2025-04-17
Completion
2025-04-17

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07765381 on ClinicalTrials.gov